QUOTE AND NEWS
Benzinga  Aug 10  Comment 
In a report published Monday, Chardan Capital Markets analyst Gbola Amusa maintained a Buy rating on La Jolla Pharmaceutical Company (NASDAQ: LJPC), with a price target of $60. Analyst Gbola Amusa commented, “Post Q2 results, we update our...
GenEng News  Jul 31  Comment 
Scientists at the La Jolla Institute for Allergy and Immunology say they have identified a pair of master regulators that control the fate of follicular helper T (TFH) cells, which are essential for inducing a strong and lasting antibody response...
Benzinga  Jul 13  Comment 
Between 10:05 a.m. EST and 10:10 a.m. EST on Monday, shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) dipped suddenly by over a percent. The Street Sweeper published a bearish report on the company at 10:07. The Street Sweeper is one of...
Benzinga  Jul 13  Comment 
http://www.thestreetsweeper.org/undersurveillance/La_Jolla_Pharmaceutica... © 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga  Jul 7  Comment 
Depomed Inc (NASDAQ: DEPO) shares climbed 38 percent to $28.50. The volume of Depomed shares traded was 1871 percent higher than normal. Horizon Pharma PLC (NASDAQ: HZNP) proposed to acquire DepoMed for $29.25 per share in stock. La Jolla...
Benzinga  Jul 6  Comment 
Catabasis Pharmaceuticals Inc (NASDAQ: CATB) shares climbed 16.49 percent to reach a new 52-week high of $14.44 after the company reported that it has received the FDA Fast Track designation for CAT-1004 for the treatment of Duchenne Muscular...
Benzinga  Jul 1  Comment 
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. La Jolla Pharmaceutical Company (NASDAQ: LJPC) shares were trading sharply higher by $2.44 (9.5 percent) at $26.95 in Wednesday's session. There appears...
FierceBiotech  Jun 23  Comment 
La Jolla, CA-based Avalon Ventures led a $17 million A round for Ankasa Regenerative Therapeutics, handing over an $8.5 million tranche to an upstart biotech working on new technology for reactivating stem cells and tissue regeneration.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki